NeuroOne Medical Technologies Finalizes 1-for-6 Reverse Stock Split to Maintain Nasdaq Listing

summarizeSummary

NeuroOne Medical Technologies has finalized a 1-for-6 reverse stock split, effective April 15, 2026, to maintain its Nasdaq listing.

check_boxKey Events

• Reverse Stock Split Finalized

  The company filed an amendment to its Certificate of Incorporation to effect a 1-for-6 reverse stock split.

• Effective Date and Trading

  The reverse stock split will be effective at 5:00 p.m. ET on April 15, 2026, with split-adjusted trading commencing on Nasdaq at market open on April 16, 2026.

• Nasdaq Compliance Action

  This action follows stockholder approval on April 3, 2026, and is intended to help the company regain compliance with Nasdaq's minimum bid price requirement, as previously disclosed due to delisting risk.

auto_awesomeAnalysis

This 8-K filing finalizes the terms and effective date of the reverse stock split, a critical step for NeuroOne Medical Technologies to address its Nasdaq delisting risk. While reverse splits are generally viewed negatively as a sign of distress, this action is necessary to meet the exchange's minimum bid price requirement and maintain the company's listing. Investors should note that while the per-share price will increase, the underlying value of their total holdings and the company's market capitalization remain unchanged. This follows the stockholder approval on April 3, 2026, for a reverse split within a specified range, and the company's prior disclosure of a going concern warning and Nasdaq delisting risk in its last 10-Q.